Mirum Pharmaceuticals shares are trading higher today as Wall Street turns more constructive on the company’s rare-disease growth profile and catalyst slate. The latest leg up follows a prominent April 29, 2026 research note that maintained a Buy stance while raising a price target to $130, reinforcing expectations that Mirum’s 2026 pipeline milestones can expand the company’s growth runway. (sahmcapital.com)

The stock’s move fits a broader “setup” trade into a catalyst-heavy 2026. Mirum has guided to $630 million to $650 million in 2026 expected global net product sales and has highlighted multiple pivotal or potentially registrational data events expected over the next several quarters, beginning with topline results from the volixibat VISTAS study in primary sclerosing cholangitis expected in Q2 2026. (ir.mirumpharma.com)

Near-term, traders are watching for any updates tied to Mirum’s upcoming pipeline milestones, including the Q2 2026 VISTAS topline readout and later-2026 readouts across additional programs noted by the company in its February 25, 2026 business update. Separately, Mirum has also filed proxy materials for its annual meeting scheduled for June 15, 2026, which can become another touchpoint for updated strategy and outlook commentary. (ir.mirumpharma.com)

Today’s advance appears driven more by sentiment repricing—anchored by a new higher target and reiteration—than by a single new clinical data release. With multiple clinical milestones approaching and the company already framing 2026 as a pivotal year, MIRM’s tape is likely to stay sensitive to incremental analyst commentary, any pre-announcements around trial timelines, and any shifts in expectations for 2026 sales momentum. (sahmcapital.com)